Cargando…

A case report of a chronic migraine patient treated with three different anti-CGRP monoclonal antibodies: which parameters better represent the efficacy?

OBJECTIVE: To report the efficacy of different anti-calcitonin gene-related peptide (CGRP) monoclonal antibodies (mAbs) on headache frequency, intensity, and duration. BACKGROUND: Blockade of CGRP receptors or neuropeptide with anti-CGRP mAbs have been successfully used for several years for the pre...

Descripción completa

Detalles Bibliográficos
Autores principales:	Uzun, Sena, Frejvall, Ulf, Özkaya-Sahin, Gülsen, Sahin, Gürdal
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Neurology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10198612/ https://www.ncbi.nlm.nih.gov/pubmed/37213912 http://dx.doi.org/10.3389/fneur.2023.1176816

Ejemplares similares

Efficacy and Safety of Anti-calcitonin Gene-Related Peptide (CGRP) Monoclonal Antibodies in Preventing Migraines: A Systematic Review
por: Muddam, Meghana Reddy, et al.
Publicado: (2023)

Real-World Evidence for the Safety and Efficacy of CGRP Monoclonal Antibody Therapy Added to OnabotulinumtoxinA Treatment for Migraine Prevention in Adult Patients With Chronic Migraine
por: Mechtler, Laszlo, et al.
Publicado: (2022)

CGRP and Migraine: What Have We Learned From Measuring CGRP in Migraine Patients So Far?
por: Kamm, Katharina
Publicado: (2022)

Dural Immune Cells, CGRP, and Migraine
por: Balcziak, Louis K., et al.
Publicado: (2022)

Refractory migraine profile in CGRP‐monoclonal antibodies scenario
por: Silvestro, Marcello, et al.
Publicado: (2021)

Safety of Rimegepant, an Oral CGRP Receptor Antagonist, Plus CGRP Monoclonal Antibodies for Migraine
por: Berman, Gary, et al.
Publicado: (2020)

Change of CGRP Plasma Concentrations in Migraine after Discontinuation of CGRP-(Receptor) Monoclonal Antibodies
por: Raffaelli, Bianca, et al.
Publicado: (2023)

Case report: Monoclonal CGRP-antibody treatment in a migraine patient with a mutation in the mitochondrial single-strand binding protein (SSBP1)
por: Kaltseis, Katharina, et al.
Publicado: (2022)

Anti-CGRP Monoclonal Antibodies: the Next Era of Migraine Prevention?
por: Tso, Amy R., et al.
Publicado: (2017)

CGRP-monoclonal antibodies in difficult-to-treat chronic migraine patients
por: Schiano di Cola, Francesca, et al.
Publicado: (2022)

New Anti-CGRP Medications in the Treatment of Vestibular Migraine
por: Hoskin, Justin L., et al.
Publicado: (2022)

Acute Medication Use in Patients With Migraine Treated With Monoclonal Antibodies Acting on the CGRP Pathway: Results From a Multicenter Study and Proposal of a New Index
por: Sette, Lucia, et al.
Publicado: (2022)

Spotlight on Anti‐CGRP Monoclonal Antibodies in Migraine: The Clinical Evidence to Date
por: Pellesi, Lanfranco, et al.
Publicado: (2017)

“Triaging” Chronic Migraine Patients in Need of CGRP(r) Monoclonal Antibodies
por: Martelletti, Paolo
Publicado: (2020)

Monoclonal Antibodies Targeting CGRP: A Novel Treatment in Vestibular Migraine
por: Lovato, Andrea, et al.
Publicado: (2023)

Advances in CGRP Monoclonal Antibodies as Migraine Therapy: A Narrative Review
por: Aditya, Suruchi, et al.
Publicado: (2023)

The Vasodilatory Response to CGRP of the Anterior and Posterior Cerebral Circulation in Migraine
por: Visočnik, Darja, et al.
Publicado: (2022)

Effectiveness of Transcranial Direct Current Stimulation and Monoclonal Antibodies Acting on the CGRP as a Combined Treatment for Migraine (TACTIC): Protocol for a Randomized, Double-Blind, Sham-Controlled Trial
por: Ornello, Raffaele, et al.
Publicado: (2022)

CGRP monoclonal antibody for preventive treatment of chronic migraine: An update of meta‐analysis
por: Han, Lin, et al.
Publicado: (2019)

CGRP monoclonal antibodies in migraine: an efficacy and tolerability comparison with standard prophylactic drugs
por: Vandervorst, Fenne, et al.
Publicado: (2021)

Why are CGRP monoclonal antibodies not yet the first line treatment in migraine prevention?
por: Simioni, Caio Vinicius de Meira Grava
Publicado: (2022)

It is time anti-CGRP monoclonal antibodies be considered first-line prophylaxis for migraine
por: Kubota, Gabriel Taricani
Publicado: (2022)

Effect of switching to erenumab in non-responders to a CGRP ligand antibody treatment in migraine: A real-world cohort study
por: Overeem, Lucas Hendrik, et al.
Publicado: (2023)

Treatment of resistant chronic migraine with anti-CGRP monoclonal antibodies: a systematic review
por: Sevivas, Hugo, et al.
Publicado: (2022)

Combination CGRP monoclonal antibody and onabotulinumtoxinA treatment for preventive treatment in chronic migraine
por: Ailani, Jessica, et al.
Publicado: (2021)

OnabotulinumtoxinA Add-On to Monoclonal Anti-CGRP Antibodies in Treatment-Refractory Chronic Migraine
por: Argyriou, Andreas A., et al.
Publicado: (2022)

Enhanced Hemodynamic and Clinical Response to αCGRP in Migraine Patients—A TCD Study
por: Visočnik, Darja, et al.
Publicado: (2021)

Prevention of migraine with monoclonal antibodies against CGRP or the CGRP receptor: Addition to the S1 guideline: Therapy of migraine attacks and prevention of migraine. Recommendations of the Germany Society of Neurology and the German Migraine and Headache Society
por: Diener, Hans-Christoph, et al.
Publicado: (2020)

Commentary: Enhanced Hemodynamic and Clinical Response to αCGRP in Migraine Patients—A TCD Study
por: Altamura, Claudia, et al.
Publicado: (2021)

Rodent behavior following a dural inflammation model with anti-CGRP migraine medication treatment
por: Reducha, Philip V., et al.
Publicado: (2023)

CGRP in migraine
por: Tfelt-Hansen, Peer, et al.
Publicado: (2009)

CGRP and migraine
por: Cauchi, M., et al.
Publicado: (2016)

New Trends in Migraine Pharmacology: Targeting Calcitonin Gene–Related Peptide (CGRP) With Monoclonal Antibodies
por: Scuteri, Damiana, et al.
Publicado: (2019)

Potential for treatment benefit of small molecule CGRP receptor antagonist plus monoclonal antibody in migraine therapy
por: Mullin, Kathleen, et al.
Publicado: (2020)

Could the New Anti-CGRP Monoclonal Antibodies Be Effective in Migraine Aura? Case Reports and Literature Review
por: Albanese, Maria, et al.
Publicado: (2022)

Calcitonin Gene-Related Peptide (CGRP)-Targeted Monoclonal Antibodies and Antagonists in Migraine: Current Evidence and Rationale
por: Cohen, Fred, et al.
Publicado: (2022)

Monoclonal antibodies for chronic migraine and medication overuse headache: A real-world study
por: Krymchantowski, Abouch V., et al.
Publicado: (2023)

Serotonin and CGRP in Migraine
por: Aggarwal, Milan, et al.
Publicado: (2012)

A new era for migraine: Pharmacokinetic and pharmacodynamic insights into monoclonal antibodies with a focus on galcanezumab, an anti-CGRP antibody
por: Kielbasa, William, et al.
Publicado: (2019)

Plasma Levels of CGRP During a 2-h Infusion of VIP in Healthy Volunteers and Patients With Migraine: An Exploratory Study
por: Pellesi, Lanfranco, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_a3ckq24usc9280f348eui6v17k